Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome
NCT ID: NCT02851602
Last Updated: 2019-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
89 participants
INTERVENTIONAL
2013-11-18
2016-11-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to show the presence of qualitative and quantitative modifications of phospholipids and sphingolipids in HDL from obese patients compared with HDL from non-obese controls.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of High-Density Lipoprotein in Obesity Study
NCT00912236
Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood
NCT02261831
Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD
NCT02285218
Effects of Almond Intake on Atherogenic Lipoprotein Particles
NCT01792648
Exploring the Mechanism of Dietary Pattern Improving MAFLD
NCT05960396
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Obese
Blood sample
control
Blood sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* fasting glycaemia \< 1.10 g/l
* waist circumference \> 102 cm for men and 88 cm for women (criteria NCEP/ATP III)
* 2 criteria among the following 3 (NCEP/ATP III criteria for metabolic syndrome):
* triglyceridaemia ≥ 1.50 g/l
* HDL cholesterol \< 0.40 g/l for men and 0.50 g/l for women
* arterial blood pressure ≥ 130/85 mmHg or treatment for arterial hypertension
* age \> 18 years
* fasting glycaemia \< 1.10 g/l
* waist circumference \< 102 cm for men and 88 cm for women
* triglyceridaemia \< 1.50 g/l
* HDL cholesterol ≥ 0.40 g/l for men and 0.50 g/l for women
* Healthy subjects who have provided written consent
Exclusion Criteria
* Diabetes
* Diseases that interfere with lipoprotein metabolism (dysthyroidism not controlled with the treatment, kidney or liver disease)
* Treatments that interfere with lipoprotein metabolism (lipid-lowering agents, oestrogens, corticoids, retinoids, antiretroviral agents)
* Pregnancy/breast feeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VERGES 2013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.